Research Areas

1. Child and adolescent drug research (a) Autistic and related disorders; (b) Intellectual disability (mental retardation) (ADHD and other comorbid conditions); (c) Disruptive behavior disorders (Conduct Disorder and Oppositional Defiant Disorder); and (d) Attention-Deficit/Hyperactivity Disorder.
2. Instrument development for assessing problem behavior and monitoring effects of treatments such as pharmacological agents and behavior therapy.
3. Assessment of cognition, especially in relation to medication treatment.
4. Use and patterns of psychotropic drugs in patient populations.
5. Psychopharmacology in adults with intellectual disability.
6. Psychometric assessment of standardized rating scales.

Achievements and Recognitions

1. Director, O.S.U. Research Unit on Pediatric Psychopharmacology (RUPP).
2. 2003 recipient of the Career Research Scientist Award of the American Academy on Mental retardation.
3. Author of over 200 scholarly publications.
4. Co-developer of the Aberrant Behavior Checklist (ABC), an informant rating scale used in over 200 studies, thus far, of individuals with developmental disabilities.
5. Co-developer of the Nisonger Child Behavior Rating Form (NCBRF), another informant rating form for assessing young people with developmental disabilities.
6. Co-editor (with Steven Reiss) of Psychotropic Medications and Developmental Disabilities: The International Consensus Handbook.
7. Co-editor with John Werry (1999) of Practitioner's Guide to Psychoactive Drugs for Children and Adolescents(2nd Ed.). New York: Plenum Press.
8. Co-author of the Project MED (Medication EDucation) series of booklets for consumers.
9. Reviewer on several review sections for the NIH.
10. Editorial Boards: Autism Research and Treatment, 2009-present; Clinical Medicine Insights: Pediatrics, 2007-present; Clinical Medicine Insights: Psychiatry, 2007-present; Clinical Therapeutics, March 2002-present; Journal of Experimental Pharmacology, 2009-present; Journal of Intellectual and Developmental Disability, 1987-present;. Research in Developmental Disabilities, 1980-present; Associate Editor, Journal of Mental Health in Intellectual Disabilities, 2007-present.
11. Editorial review boards (now and/or in the past) for American Journal on Mental Retardation, Clinical Therapeutics, Journal of Child and Adolescent Psychopharmacology, Journal of Intellectual and Developmental Disability, Research in Developmental Disabilities; and Associate Editor, American Journal on Mental Retardation, 1993-1998.
12. Editorial Board Chair: Aman, M.G., Alvarez, N., Benefield, W., Crismon, M.L., Green, G., King, B.H., Reiss, S., Rojahn, J., & Szymanski, L. (2000), (Editorial Board). American Journal on Mental Retardation, 105, [Issue #3, Special Issue: In A.J. Rush & A. Frances (Eds.)], The Expert Consensus Guideline Series. Treatment of Psychiatric and Behavioral Problems in Mental Retardation, 159-228.
13. Member of 55 student Masters, Candidacy, and Dissertation committees.

Publications with Graduate Students

Farmer, C.A. & Aman, M.G. (2010). Psychometric properties of the Children’s Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP). Research in Developmental Disabilities, 31, 270-280. [doi:10.1016/j.ridd.2009.03.001]

Chowdhury, M., Aman, M.G., Scahill, L., Swiezy, N.B., Arnold, L.E., Lecavalier, L., Johnson, C.R., Handen, B.L., Stigler, K.A., Bearss, K., Sukhodolsky, D.G., & McDougle, C.J. (2010). The Home Situations Questionnaire–PDD Version: Factor structure and Psychometric Properties. Journal of Intellectual Disabilities Research, 54, 281-291. doi:10.1111/j.1365-2788.2010.01259.x

Farmer, C.A. & Aman, M.G. (In press). Aggressive behavior in a sample of children with autism spectrum disorders. Research in Autism Spectrum Disorders.

Matlock, S.T. & Aman, M.G. (In press). Development of the Adult Scale of Hostility and Aggression: Reactive/Proactive (A-SHARP). Submitted to American Journal on Intellectual and Developmental Disabilities.

Aman, M.G., Hollway, J.A., Leone, S., Masty, J., Lindsay, R.L., Nash, P. & Arnold, L.E. (2009). Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. Research in Developmental Disabilities, 30, 386-396.

Aman, M.G., McDougle, C.J., Scahill, L., Handen, B., Arnold, LE., Johnson, C. Stigler, K.A., Bearss, K., Butter, E., Swiezy, N.B., Sukhodolsky, D.D., Ramadan, Y., Pozdol, S.L., Nikolov, R., Lecavalier, L., Kohn, A.E., Koenig, K., Hollway, J.A., Korzekwa, P., Gavaletz, A., Mulick, J.A., Hall, K.L., Dziura, J., Ritz, L., Trollinger, S., Yu, S., Vitiello, B., Wagner, A. (Research Units on Pediatric Psychopharmacology). (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1143-1154.

Farmer, C. & Aman, M. (2009). Development of the Children’s Scale for Hostility and Aggression: Reactive/Proactive. Research in Developmental Disabilities, 30, 1155-1167.

Jahromi, C.L. Kasari, McCracken, J.T., Lee, L.S. Aman, M.G., McDougle, C.J., Scahill, L., Tierney, E., Arnold, L.E., Vitiello, B., Ritz, L., Witwer, A., Kustan, E., Ghuman, J., & Posey, D.J.. (2009). Positive effects of methylphenidate on social communication and self-regulation in children with pervasive developmental disorders and hyperactivity. Journal of Autism and Developmental Disorders 39, 395-404.

Aman , M.G. & Farmer, C.A. (2008). Psychotropic medication research in children and adolescents: Ethical implications. Journal of Empirical Research on Human Research Ethics, 3, 39-47. PRINT ISSN 1556-2646, ONLINE ISSN 1556-2654.

Aman, M.G., Farmer, C.A., Hollway, J.A., & Arnold, L.E. (2008). Treatment of Inattention, overactivity, and impulsiveness in autism spectrum disorders. Child and Adolescent Psychiatric Clinics of North America (D. Posey &C. McDougle, Guest Editors), 17, 713–738.

Aman, M.G., Hollway, J.A., McDougle, C.J., Scahill, L., Tierney, E., McCracken, J., Arnold, L.E., Vitiello, B., Ritz, L., Gavaletz, A., Cronin, P., Swiezy, N.B., Wheeler, C., Koenig, K., Ghuman, J., & Posey, D.J. (2008). Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology, 18, 227-236.

Aman, M.G., Leone, S., Lecavalier, L., Park, L., Buican, B., & Coury, D. (2008). The Nisonger Child Behavior Rating Form—Typical IQ Version, for children with typical IQ. International Clinical Psychopharmacology, 23, 232-242.

Aman, M.G., Benson, B., Farmer, C.A., Hall, K., & Malone, K. (2007). Project MED: Effects of a Medication Education booklet series for individuals with intellectual handicaps. Intellectual and Developmental Disabilities, 45, 33-45.

Aman, M.G., Vinks, A.A., Remmerie, B., Mannaert, E., Ramadan, Y., Masty, J., Lindsay, R.L., & Malone, K. (2007). Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clinical Therapeutics, 29, 1476-1486.

Lam, K.S.L. & Aman, M.G. (2007). The Repetitive Behavior ScaleCRevised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders, 37, 855-866.

Arnold, L.E., Aman, M.G., Cook, A., Witwer, A., Hall, K., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autistic spectrum disorders: Placebo-controlled crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1196-1205.

Lam, K.L.S., Aman, M.G., & Arnold, L.E. (2006). Neurochemical correlates of Autistic disorder: A review of the literature. Research in Developmental Disabilities, 27, 254-289.

Lecavalier, L., Aman, M.G., Scahill, L., McDougle, C.J., Vitiello, B., Tierney, E., McCracken, J.T., Arnold, L.E., Ghuman, J.K., Posey, D.J., Koenig, K., Cronin, P., Lofton, R.L., Martin, A., Hollway, J., Kau, A.S., Lee, L. (2006). The validity of the Autism Diagnostic Interview−Revised. American Journal on Mental Retardation, 111, 199-215.

Scahill, L., McDougle, C.J., Williams, S., Dimitropoulos, A., Aman, M.G., McCracken, J., Tierney, E., Arnold, L.E., Lam, K.L., Vitiello, B.. (2006). The Children=s Yale-Brown Obsessive-Compulsive Scales modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1114-1123.

Scahill, L., McDougle, C.J., Williams, S., Dimitropoulos, A., Aman, M.G., McCracken, J., Tierney, E., Arnold, L.E., Lam, K.L., Vitiello, B.. (In press). The Children=s Yale-Brown Obsessive-Compulsive Scales modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry.

Lam, K.S.L. & Aman, M.G. (In press). The Repetitive Behavior Scale Revised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders.

Aman, M.G., Benson, B., Farmer, C.A., Hall, K., & Pappas, K. (In press). Project MED: Effects of a Medication Education booklet series for individuals with intellectual handicaps. Mental Retardation.

Lam, K.L.S., Aman, M.G., & Arnold, L.E. (2006). Neurochemical correlates of Autistic disorder I A review of the literature. Research in Developmental Disabilities, 27, 254-289.

McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E.,Davies, M., Arnold, L.E., Posey, D.J., Martin, A., Ghuman, J.K., Shah, B., Chuang, S.Z., Swiezy, N.B., Gonzalez, N.M., Hollway, J., Koenig, K., McGough, J., Ritz, L., Vitiello, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry, 162, 1142-1148.

Arnold, L.E., Aman, M.G., Cook, A., Witwer, A., Hall, K., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autistic spectrum disorders: Placebo-controlled crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1196-1205.

Aman, M.G., Lam, K.S.L., & Van Bourgondien, M.E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15, 116-126.

Shultz, J., Aman, M.G., Kelbley, T., Wallace, C.L.,Burt, D.B., Primeaux-Hart, S., Loveland, K., Thorpe, L., Bogos, E.S., Timon, J., Patti, P., & Tsiouris, J. (2004). Evaluation of screening tools for dementia in older persons with mental retardation. American Journal on Mental Retardation, 109, 98-110.

Lindsay, R.L., Leone, S., & Aman, M.G. (2004). Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders. Clinical Pediatrics, 43, 437-444.

Brown, E.C., & Aman, M. G., & Lecavalier (2004). Empirical classification of behavioral and psychiatric problems in children with mental retardation. American Journal on Mental Retardation, 109, 445-455.

Hanley, B., Tasse, M.J., Aman, M.G., & Pace, P. (2003). Psychometric properties of the Family Needs Scale.Journal of Child and Family Studies, 12, 41-48.

Esbensen, A.J., Rojahn, J., Aman, M.G., & Ruedrich, S. (2003). Development of an instrument assessing affective symptoms in individuals with mental retardation. Journal of Autism and Developmental Disorders, 33, 617-629.

Aman, M.G., Lam, K.L., & Collier-Crespin, A. (2003). Prevalence and patterns of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527-534.

Langworthy-Lam, K.L., Aman, M.G., & Van Bourgondien, M.E. (2002). Prevalence and patterns of use of psychoactive medicines in individuals with autism in the Autism Society of North Carolina. Journal of Child and Adolescent Psychopharmacology, 12, 311-321.

Brown, E.C., Aman, M. G., & Havercamp, S. M. (2002). Factor analysis and norms on parent ratings with the Aberrant Behavior Checklist Community for young people in special education. Research in Developmental Disabilities, 23, 45-60.

Aman, M.G., Armstrong, S., Buican, B., & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities, 23, 119-134.

Esbensen, A.J., Rojahn, J., Aman, M.G., & Ruedrich, S (2001). Development of an assessment instrument for anxiety, depression and mood among individuals with mental retardation. The NADD Bulletin, 4, 83-84.

Aman, M.G. & Langworthy, K.S. (2000). Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30, 451-459.

Aman, M. G., Arnold L. E., & Armstrong, S. C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 279-289.

Shultz, J.M., Aman, M.G., & Rojahn, J. (1998). Psychometric evaluation of a measure of cognitive decline in elderly people with mental retardation. Research in Developmental Disabilities, 19, 63-71.

DeWitt, M.B., Aman, M.G., & Rojahn, J. (1997). Effects of reinforcement schedules on cognitive tests in children with mental retardation and ADHD. Journal of Developmental and Physical Disabilities, 9, 101-115.

Sarphare, G. & Aman, M. G. (1996). Parent- and self-ratings of anxiety in children with mental retardation: Agreement levels and test-retest reliability. Research in Developmental Disabilities, 17, 27-39.

Aman, M.G., Van Bourgondien, M.E., Wolford, P.C., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.

Aman, M. G., Sarphare, G., & Burrow, W. (1995). Psychoactive drugs in group homes: Prevalence and relation to demographic/psychiatric variables. American Journal on Mental Retardation, 99, 500-509.

Aman, M. G., Rojahn, J., King, E. H., Logsdon, D. A., & Marshburn, E. (1994). Prevalence and pattern of prescribed medication in two year old children. Journal of Developmental and Physical Disabilities (Special issue on psychopharmacology),6, 87-99.

Rojahn, J., Aman, M. G., Marshburn, E., Moeschberger, M., King, E., Logsdon, D. A., & Schroeder, S. R. (1993). Biological and environmental risk for poor developmental outcome in young children. American Journal on Mental Retardation, 97, 702-708.

Glasspoole, L. A. & Aman, M. G. (1990). Knowledge, attitudes, and happiness of nurses working with gerontological patients. Journal of Gerontological Nursing, 16, 11 14.

Glasspoole, L. A. & Aman, M. G. (1988). Attitudes and knowledge of gerontological nurses toward psychotropic drugs. The Gerontologist, 28, 667 671.

Selected Publications

Farmer, C.A. & Aman, M.G. (In press). Aggressive behavior in a sample of children with autism spectrum disorders. Research in Autism Spectrum Disorders.

Matlock, S.T. & Aman, M.G. (In press). Development of the Adult Scale of Hostility and Aggression: Reactive/Proactive (A-SHARP). Submitted to American Journal on Intellectual and Developmental Disabilities.

Farmer, C.A. & Aman, M.G. (2010). Psychometric properties of the Children’s Scale of Hostility and Aggression: Reactive/Proactive (C-SHARP). Research in Developmental Disabilities, 31, 270-280. [doi:10.1016/j.ridd.2009.03.001]

Aman, M.G., Hollway, J.A., Leone, S., Masty, J., Lindsay, R.L., Nash, P. & Arnold, L.E. (2009). Effects of risperidone on cognitive-motor performance and motor movements in chronically medicated children. Research in Developmental Disabilities, 30, 386-396.

Aman, M.G., McDougle, C.J., Scahill, L., Handen, B., Arnold, LE., Johnson, C. Stigler, K.A., Bearss, K., Butter, E., Swiezy, N.B., Sukhodolsky, D.D., Ramadan, Y., Pozdol, S.L., Nikolov, R., Lecavalier, L., Kohn, A.E., Koenig, K., Hollway, J.A., Korzekwa, P., Gavaletz, A., Mulick, J.A., Hall, K.L., Dziura, J., Ritz, L., Trollinger, S., Yu, S., Vitiello, B., Wagner, A. (Research Units on Pediatric Psychopharmacology). (2009). Medication and parent training in children with pervasive developmental disorders and serious behavior problems: Results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1143-1154.

Handen, B.L., Melmed, R.D., Hansen, R.L., Aman, M.G., Burnham, D., Bruss, J., & McDougle, C..J. (2009). A Double-blind, placebo-controlled trial of oral human immunoglobulin for gastrointestinal dysfunction in children with autistic disorder. Journal of Autism and Developmental Disorders, Epub. 16 January 2009. DOI 101007/s10803-008-0687-y

Karabekiroglu, K. & Aman, M.G. (2009). Adaptation and validity of Aberrant Behavior ChecklistCommunity in a psychiatric clinical sample of toddlers. Child Psychiatry and Human Development, 40, 99-110. Electronic: DOI 10.1007/s10578-008-0108-7

Esbensen, A., Seltzer, M., Greenberg, J., & Aman, M.G. (2009). A longitudinal investigation of psychoactive and physical medication use among adolescents and adults with autism spectrum disorders. Journal of Autism and Developmental Disorders, 39, 1339-1349.

Farmer, C. & Aman, M. (2009). Development of the Children’s Scale for Hostility and Aggression: Reactive/Proactive. Research in Developmental Disabilities, 30, 1155-1167.

Marcus, R.N., Owen, R., Kamen, L., Manos, G., McQuade, R.D., Carson, W.H., & Aman, M.G. (2009). A double-blind, randomized, placebo-controlled study of fixed-dose aripiprazole in children and adolescents with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 48, 1110-1119. DOI:10.1097/CHI.0b013e3181b76658.

Aman , M.G. & Farmer, C.A. (2008). Psychotropic medication research in children and adolescents: Ethical implications. Journal of Empirical Research on Human Research Ethics, 3, 39-47. PRINT ISSN 1556-2646, ONLINE ISSN 1556-2654.

Aman, M.G., Hollway, J.A., McDougle, C.J., Scahill, L., Tierney, E., McCracken, J., Arnold, L.E., Vitiello, B., Ritz, L., Gavaletz, A., Cronin, P., Swiezy, N.B., Wheeler, C., Koenig, K., Ghuman, J., & Posey, D.J. (2008). Cognitive effects of risperidone in children with autism and irritable behavior. Journal of Child and Adolescent Psychopharmacology, 18, 227-236.

Aman, M.G., Leone, S., Lecavalier, L., Park, L., Buican, B., & Coury, D. (2008). The Nisonger Child Behavior Rating Form—Typical IQ Version, for children with typical IQ. International Clinical Psychopharmacology, 23, 232-242.

Aman, M.G., Vinks, A.A., Remmerie, B., Mannaert, E., Ramadan, Y., Masty, J., Lindsay, R.L., & Malone, K. (2007). Plasma pharmacokinetic characteristics of risperidone and their relationship to saliva concentrations in children with psychiatric or neurodevelopmental disorders. Clinical Therapeutics, 29, 1476-1486.

Lam, K.S.L. & Aman, M.G. (2007). The Repetitive Behavior ScaleCRevised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders, 37, 855-866.

Posey, D.J., Aman, M.G., McCracken, J.T., Scahill, L., Tierney, E., Arnold, L.E., Vitiello, B., Chuang, S.Z., Davies, M., Ramadan, Y., Witwer, A., Swiezy, N.B., Cronin, P., Shah, B., Carroll, D., Young, C., Wheeler, C., & McDougle, C.J. (2007). .Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry, 61, 538-544.

Research Units on Pediatric Psychopharmacology [RUPP] Autism Network (Including Aman, M.G., PI at O.S.U. site). (2007). Parent training for children with pervasive developmental disorders: A multi-site feasibility trial. Behavior Interventions, 22, 179-199.

Tierney E, Aman MG, Stout DJ, Pappas K, Arnold E, Vitiello B, Scahill L, McDougle CJ, McCracken JT, Wheeler C, Martin A, Posey DJ, Shah B. (2007). Parent satisfaction in a multi-site trial of risperidone in children with autism: A social validity study. Psychopharmacology, 191, 149-157. Epub 200 6 Nov 23; e-published 23 November 2006.

Aman, M.G. & Handen, B. Reactions to “Ethical challenges and complexities of including people with intellectual disability as participants in research” by Dr. Teresa Iacono (2006). Journal of Intellectual and Developmental Disabilities, 31, 1-3.

Arnold, L.E., Aman, M.G., Cook, A., Witwer, A., Hall, K., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autistic spectrum disorders: Placebo-controlled crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1196-1205.

Lam, K.L.S., Aman, M.G., & Arnold, L.E. (2006). Neurochemical correlates of Autistic disorder: A review of the literature. Research in Developmental Disabilities, 27, 254-289.

Lecavalier, L., Aman, M.G., Scahill, L., McDougle, C.J., Vitiello, B., Tierney, E., McCracken, J.T., Arnold, L.E., Ghuman, J.K., Posey, D.J., Koenig, K., Cronin, P., Lofton, R.L., Martin, A., Hollway, J., Kau, A.S., Lee, L. (2006). The validity of the Autism Diagnostic Interview−Revised. American Journal on Mental Retardation, 111, 199-215.

Williams, S.K., Scahill, L., Vitiello, B., Aman, M.G., Arnold, L.E., McDougle, C.J., McCracken, J.T., Tierney, E., Ritz, L., Posey, D.J., Swiezy, N.B., Hollway, J., Cronin, P., Ghuman, J., Wheeler, C., Cicchetti, D., & Sparrow, S. (2006). Risperidone and adaptive behavior in children with autism. Journal of the American Academy of child and Adolescent Psychiatry, 45, 431-439.

Lindsay, R.L., Arnold, L.E., Aman, M.G, Vitiello, B., Posey, D.J., McDougle, C.J., Scahill, L., Pachler, M., McCracken, J.T., Tierney, E., & Bozzolo, D. (2006). Nutritional balance in autism: Changes with risperidone treatment. Journal of Intellectual and Developmental Disabilities, 31, 204-209.

Scahill, L., McDougle, C.J., Williams, S., Dimitropoulos, A., Aman, M.G., McCracken, J., Tierney, E., Arnold, L.E., Lam, K.L. Vitiello, B.. (2006). The Children=s Yale-Brown Obsessive-Compulsive Scales modified for pervasive developmental disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1114-1123.

Aman, M.G., Benson, B., Farmer, C.A., Hall, K., & Pappas, K. (In press). Project MED: Effects of a Medication Education booklet series for individuals with intellectual handicaps. Mental Retardation.

Arnold, L.E., Aman, M.G., Cook, A., Witwer, A., Hall, K., Thompson, S., & Ramadan, Y. (2006). Atomoxetine for hyperactivity in autistic spectrum disorders: Placebo-controlled crossover trial. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1196-1205.

Lam, K.S.L. & Aman, M.G. (In press). The Repetitive Behavior ScaleCRevised: Independent validation in individuals with autism spectrum disorders. Journal of Autism and Developmental Disorders.

Pandina, G. Bilder, R., Harvey, P.D., Keefe, R.S.E., Aman, M.G. & Gharabawi, G. (In press). Risperidone and cognitive function in children with disruptive behavior disorders. Biological Psychiatry.

Posey, D.J., Aman, M.G., McCracken, J.T., Scahill, L., Tierney, E., Arnold, L.E., Vitiello, B., Chuang, S.Z., Davies, M., Ramadan, Y., Witwer, A., Swiezy, N.B., Cronin, P., Shah, B., Carroll, D., Young, C., Wheeler, C., & McDougle, C.J. (In press). .Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: An analysis of secondary measures. Biological Psychiatry.

Research Units on Pediatric Psychopharmacology [RUPP] Autism Network (Including Aman, M.G., PI at O.S.U. site). (In press). Parent training for children with Pervasive Developmental Disorders: A multi-site feasibility trial. Behavior Interventions.

Scahill, L., Aman, M.G., McDougle, C.J., McCracken, J.T., Tierney, E., Dziura, J., Arnold, L.E., Posey, D., Young, C., Shah, B., Ghuman, J., Ritz, L., & Vitiello, B. (In press). A prospective open trial of guanfacine in children with pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology.

Tierney, E., Aman, M.G., Stout, D.J., Pappas, K., Arnold, E., Vitiello, B., Scahill, L., McDougle, C.J., McCracken, J.T., Wheeler, C., Martin, A., Posey, D.J., & Shah, B. (In press). Parent Satisfaction in a Multi-Site Trial of Risperidone in Children with Autism: A Social Validity Study, Parent Satisfaction in a Multi-Site Trial of Risperidone in Children with Autism: A Social Validity Study. Psychopharmacology.

Aman, M.G. & Handen, B. Reactions to “Ethical challenges and complexities of including people with intellectual disability as participants in research” by Dr. Teresa Iacono (2006). Journal of Intellectual and Developmental Disabilities, 31, 1-3.

Pandina, G., Aman, M.G., & Findling, R.L. (2006). Risperidone in the management of disruptive behavior disorders. Journal of Child and Adolescent Psychopharmacology, 16, 379-392.

Lam, K.L.S., Aman, M.G., & Arnold, L.E. (2006). Neurochemical correlates of Autistic disorder I A review of the literature. Research in Developmental Disabilities, 27, 254-289.

Lecavalier, L., Aman, M.G., Scahill, L., McDougle, C.J., Vitiello, B., Tierney, E., McCracken, J.T., Arnold, L.E., Ghuman, J.K., Posey, D.J., Koenig, K., Cronin, P., Lofton, R.L., Martin, A., Hollway, J., Kau, A.S., Lee, L. (2006). The validity of the Autism Diagnostic Interview−Revised. American Journal on Mental Retardation, 111, 199-215.

Aman, M.G. (2005). Treatment planning for patients with autism spectrum disorders. Journal of Clinical Psychiatry, 66 (supplement 10), 38-45.

Aman, M.G., Arnold, L.E., McDougle, C.J. Vitiello, B., Scahill, L., Davies, M., McCracken, J.T., Tierney, E., Nash, P.L., Posey, D.J. Chuang, S., Martin, A., Shah, B., Gonzalez, N.M, Swiezy, N.B., Ritz, L., Koenig, K., McGough, J., Ghuman, J.K., & Lindsay, R.L. (2005). Acute and long-term safety and tolerability of risperidone in children with autism. Journal of Child and Adolescent Psychopharmacology, 15, 869-884.

Aman, M.G., Lam, K.S.L., & Van Bourgondien, M.E. (2005). Medication patterns in patients with autism: Temporal, regional, and demographic influences. Journal of Child and Adolescent Psychopharmacology, 15, 116-126.

Lord, C., Wagner, A., Rogers, S., Szatmari, P., Aman, M., Charman, T., Dawson, G., Durand, V.M., Grossman, L., Guthrie, D., Harris, S., Kasari, C., Marcus, L., Murphy, S., Odom, S., Pickles, A., Scahill, L., Shaw, E., Siegel, B., Sigman, M., Stone, W., Smith, T., & Yoder, P. (2005). Challenges in evaluating psychosocial interventions for autistic spectrum disorders. Journal of Autism and Developmental Disorders, 35, 695-708.

McDougle, C.J., Scahill, L., Aman, M.G., McCracken, J.T., Tierney, E.,Davies, M., Arnold, L.E., Posey, D.J., Martin, A., Ghuman, J.K., Shah, B., Chuang, S.Z., Swiezy, N.B., Gonzalez, N.M., Hollway, J., Koenig, K., McGough, J., Ritz, L., Vitiello, B. (2005). Risperidone for the core symptom domains of autism: Results from the study by the Autism Network of the Research Units on Pediatric Psychopharmacology. American Journal of Psychiatry, 162, 1142-1148.

Research Units on Pediatric Psychopharmacology Autism Network (Aman, M.G., Arnold, L.E., Ramadan, Y., Witwer, A., Lindsey, R.,., McDougle, C.J., Posey, D., Swiezy, N., Kohn, A., McCracken, J.T., Shah, B., Cronin, P., McGough, J., Lee, L., Scahill L., Martin, A., Koenig, K., Carroll, D., Young, C., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N.M., Grados, M). (2005). A randomized, double-blind, placebo-controlled, crossover trial of methylphenidate in children with hyperactivity associated with pervasive developmental disorders. Archives of General Psychiatry, 62, 1266-1274.

Research Units on Pediatric Psychopharmacology Autism Network (Aman, M.G., Arnold, L.E., Lindsay, R., Nash, P., Hollway, J., McCracken, J.T., McGough, J., Shah, B., Cronin, P., Hong, D., McDougle, C.J., Posey, D., Swiezy, N., Kohn, A., Scahill L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N.M., Grados, M.). (2005). Risperidone treatment of autistic disorder: Longer term benefits and blinded discontinuation after six months. American Journal of Psychiatry, 162, 1361-1369.

Aman, M.G. (2004). Management of hyperactivity and other acting-out problems in patients with autism spectrum disorders, Seminars in Pediatric Neurology, 11 (3), 225-228.

Aman, M.G., Binder, C., & Turgay, A. (2004). Risperidone effects in the presence of psychostimulant medicine in children with ADHD and disruptive behavior disorders. Journal of Child and Adolescent Psychopharmacology, 14, 243-254.

Aman, M.G., Novotny, S., Samango-Sprouse, C., Lecavalier, L., Leonard, E., Gadow, K., King, B., Pearson, D.A., Gernsbacher, M.A., & Chez, M. (2004). Outcome measures for clinical drug trials in autism. CNS Spectrums, 9, 36-47.

Lecavalier, L., Aman, M.G., Hammer, D., Stoica, W., & Matthews, G.L. (2004). Factor analysis of the Nisonger Child Behavior Rating Form in children with autism spectrum disorders. Journal of Autism and Developmental Disorders, 34, 709-721.

Shultz, J. Aman, M.G., Kelbley, T., Wallace, C.L.,Burt, D.B., Primeaux-Hart, S., Loveland, K., Thorpe, L., Bogos, E.S., Timon, J., Patti, P., & Tsiouris, J. (2004). Evaluation of screening tools for dementia in older persons with mental retardation. American Journal on Mental Retardation, 109, 98-110.

Aman, M.G., Buican, B., & Arnold, L.E. (2003). Methylphenidate treatment in children with low IQ and ADHD: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 27-38.

Aman, M.G., Lam, K.L., & Collier-Crespin, A. (2003). Prevalence and patterns of psychoactive medicines among individuals with autism in the Autism Society of Ohio. Journal of Autism and Developmental Disorders, 33, 527-534.

Aman, M.G., Armstrong, S., Buican, B., & Sillick, T. (2002). Four-year follow-up of children with low intelligence and ADHD: A replication. Research in Developmental Disabilities, 23, 119-134.

Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., Findling, R.L., & The Risperidone Disruptive Behavior Study Group. (2002). Risperidone treatment of children with disruptive behavior disorders and subaverage IQ: A double-blind, placebo-controlled study. American Journal of Psychiatry, 159, 1337-1346.

Research Units on Pediatric Psychopharmacology Autism Network (McCracken, J.T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M.G., Arnold, L.E., Lindsay, R., Nash, P., Hollway, J., McDougle, C.J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N.M., Grados, M., Vitiello, B., Ritz, L.,Davies, M., Robinson, J., McMahon, D.) (2002). A double-blind, placebo-controlled trial of risperidone in children with autistic disorder. The New England Journal of Medicine, 347(no.5), 314-321.3

Scahill, L., McCracken, J., McDougle, C.J., Aman, M.G., Arnold, L.E., Tierney, E., Cronin, P., Davies, M., Ghuman, J., Gonzalez, N., Koenig, K., Lindsay, R., Martin, A., McGough, J., Posey, D.J., Swiezy, N., Volkmar, F., Ritz, L., & Vitiello, B. (2001). Methodological issues in designing a multisite trial of risperidone in children and adolescents with autism. Journal of Child and Adolescent Psychopharmacology, 11, 377-388.

Aman, M.G., Alvarez, N., Benefield, W., Crismon, M.L., Green, G., King, B.H., Reiss, S., Rojahn, J., & Szymanski, L. (2000). (Editorial Board). American Journal on Mental Retardation, 105, [Issue #3, Special Issue: In A.J. Rush & A. Frances (Eds.)], The Expert Consensus Guideline Series. Treatment of Psychiatric and Behavioral Problems in Mental Retardation, 159-228.

Aman, M.G. & Langworthy, K.S. (2000). Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. Journal of Autism and Developmental Disorders, 30, 451-459.

Aman, M. G., Arnold L. E., & Armstrong, S. C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 279-289.

Aman, M.G. & Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities Research Reviews, 5, 253-263.

Werry, J.S. & Aman, M.G. (1999). Practitioner's guide to psychoactive drugs for children and adolescents (2nd ed.). New York: Plenum Press.

Reiss, S. & Aman, M.G. (1998). Psychotropic medications and developmental disabilities: The international consensus handbook. Columbus, OH: The Nisonger Center UAP.

Shultz, J.M., Aman, M.G., & Rojahn, J. (1998). Psychometric evaluation of a measure of cognitive decline in elderly people with mental retardation. Research in Developmental Disabilities, 19, 63-71.

Aman, M. G., Kern, R. A., Osborne, P., Tumuluru, R., Rojahn, J., & del Medico, V. (1997). Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Clinical effects. American Journal on Mental Retardation, 101, 521-534.

Aman, M. G. (1996). Stimulant drugs in the developmental disabilities revisited. Journal of Developmental and Physical Disabilities, 8, 347-365.

Aman, M. G., Tassé, M. J., Rojahn, J., & Hammer, D. (1996). The Nisonger CBRF: A child behavior rating form for children with developmental disabilities. Research in Developmental Disabilities, 17,41-57.

Aman, M. G., Burrow, W. H., & Wolford, P. L. (1995). The Aberrant Behavior ChecklistCCommunity: Factor validity and effect of subject variables for adults in group homes. American Journal on Mental Retardation, 100, 283-292.

Aman, M. G., Sarphare, G., & Burrow, W. (1995). Psychoactive drugs in group homes: Prevalence and relation to demographic/psychiatric variables. American Journal on Mental Retardation, 99, 500-509.

Aman, M.G., Van Bourgondien, M.E., Wolford, P.C., & Sarphare, G. (1995). Psychotropic and anticonvulsant drugs in subjects with autism: Prevalence and patterns of use. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 1672-1681.

Aman, M.G. & Wolford, P.L. (1995). Consumer satisfaction with involvement in drug research: A social validity study. Journal of the American Academy of Child and Adolescent Psychiatry, 34, 940-945.

Einfeld, S. L., & Aman, M. G. (1995). Issues in the taxonomy of psychopathology in children and adolescents with mental retardation. Journal of Autism and Developmental Disorders, 25, 143-167.

Aman, M. G. & Rojahn, J. (1994). The psychometric characteristics of the Preschool Behavior Questionnaire in preschoolers with developmental handicaps. Journal of Developmental and Physical Disabilities, 6, 1-15.

Aman, M. G. & Singh, N. N. (1994). Aberrant Behavior Checklist - Community. Supplementary Manual. East Aurora, NY: Slosson Educational Publications.

Aman, M. G., Kern, R. A., McGhee, D. E., & Arnold, L. E. (1993). Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 851-859.

Aman, M. G., Kern, R. A., McGhee, D. E., & Arnold, L. E. (1993). Fenfluramine and methylphenidate in children with mental retardation and ADHD: Laboratory effects. Journal of Autism and Developmental Disorders, 23, 491-506.

Aman, M. G., Werry, J. S., & Turbott, S. H. (1992). Behavior of children with seizures: Comparison with norms and effect of seizure type. The Journal of Nervous and Mental Disease, 180, 124 129.

Aman, M. G. (1991). Review and evaluation of instruments for assessing emotional and behavioural disorders.Australia and New Zealand Journal of Developmental Disabilities, 17, 127 145.

Aman, M. G. & Kern, R. A. (1990/1991). The efficacy of folic acid in fragile X syndrome and other developmental disabilities. Journal of Child and Adolescent Psychopharmacology, 1, 285 295.

Aman, M. G., Marks, R. E., Turbott, S. H., Wilsher, C. P., & Merry, S. N. (1991). Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 246 256.

Aman, M. G., Marks, R. E., Turbott, S. H., Wilsher, C. P. & Merry, S. N. (1991). Methylphenidate and thioridazine in the treatment of intellectually subaverage children: Effects on cognitive motor performance. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 816 824.

Aman, M. G. (1990). Considerations in the use of psychotropic drugs in elderly mentally retarded persons. Journal of Mental Deficiency Research, 34, 1 10.

Aman, M. G., Werry, J. S., Paxton, J. W., Turbott, S. H., & Stewart, A. W. (1990). Effects of carbamazepine on psychomotor performance in children as a function of drug concentration, seizure type, and time of medication.Epilepsia, 31, 51 60.

Aman, M. G. & Kern, R. A. (1989). Review of fenfluramine in the treatment of the developmental disabilities.Journal of the American Academy of Child and Adolescent Psychiatry, 28, 549 565.

Aman, M. G., Teehan, C. J., White, A. J., Turbott, S. H., & Vaithianathan, C. (1989). Haloperidol treatment with chronically medicated residents: Dose effects on clinical behavior and reinforcement contingencies. American Journal on Mental Retardation, 93, 452 460.

Aman, M. G. (1987). (Guest editorial.) Overview of pharmacotherapy: Current status and future directions.Journal of Mental Deficiency Research, 31, 121 130.

Aman, M. G., Richmond, G., Stewart, A. W., Bell, J. C., & Kissel, R. C. (1987). The Aberrant Behavior Checklist: Factor structure and the effect of subject variables in American and New Zealand facilities. American Journal of Mental Deficiency, 91, 570 578.

Aman, M. G., Singh, N. N., & Turbott, S. H. (1987). Reliability of the Aberrant Behavior Checklist and the effect of variations in instructions. American Journal of Mental Deficiency, 92, 237 240.

Aman, M. G., Paxton, J. W., Field, C. J., & Foote, S. E. (1986). Prevalence of toxic anticonvulsant drug concentrations in mentally retarded persons with epilepsy. American Journal of Mental Deficiency, 90, 643 650.

Aman, M. G., & Singh, N. N. (1986). Aberrant Behavior Checklist Manual. East Aurora, NY: Slosson Educational Publications.

Aman, M. G., & Singh, N. N. (1986). A critical appraisal of recent drug research in mental retardation: The Coldwater studies. Journal of Mental Deficiency Research, 30, 203 216.

Aman, M. G., & Turbott, S. H. (1986). Incidental learning, distraction, and sustained attention in hyperactive and control subjects. Journal of Abnormal Child Psychology, 14, 441 455.

Aman, M. G., Field, C. J., & Bridgman, G. D. (1985). City wide survey of drug patterns among non institutionalized retarded persons. Applied Research in Mental Retardation, 6, 159 171.

Aman, M. G., Singh, N. N., Stewart, A. W., & Field, C. J. (1985). The Aberrant Behavior Checklist: A behavior rating scale for the assessment of treatment effects. American Journal of Mental Deficiency, 89, 485-491.

Aman, M.G., Singh, N.N., Stewart, A.W., & Field, C.J. (1985). Psychometric characteristics of the Aberrant Behavior Checklist. American Journal of Mental Deficiency, 89, 492-502.

Aman, M. G., & Werry, J. S. (1984). The Revised Behavior Problem Checklist in clinic attenders and non attenders: Age and sex effects. Journal of Clinical Child Psychology, 13, 237 242.

Aman, M. G. (1982). Stimulant drug effects in developmental disorders and hyperactivity: Toward a resolution of disparate findings. Journal of Autism and Developmental Disorders, 12, 385 398.

Aman, M. G., & Werry J. S. (1982). Children's reading disorders: Problems of definition and a two year follow up.Australian Paediatric Journal, 18, 268 272.

Singh, N. N., & Aman, M. G. (1981). Mental retardation: State of the field in New Zealand. Applied Research in Mental Retardation, 2, 115 127.

Singh, N. N., & Aman, M. G. (1981). Effects of thioridazine dosage on the behavior of severely mentally retarded persons. American Journal of Mental Deficiency, 85, 580 587.

Aman, M. G., & Singh, N. N. (1980). The usefulness of thioridazine for treating childhood disorders Fact or folklore? American Journal of Mental Deficiency, 84, 331 338.

Aman, M. G. (1979). Cognitive, social, and other correlates of specific reading retardation. Journal of Abnormal Child Psychology, 7, 153 168.

Werry, J. S., & Aman, M. G. (1975). Methylphenidate and haloperidol in children. Effects on attention, memory, and activity. Archives of General Psychiatry, 32, 790 795.

Other Publications

1. Aman, M. G. (2006, October update). Annotated Bibliography on the Aberrant Behavior Checklist (ABC). Unpublished manuscript, The Nisonger Center UCEDD, Ohio State University, Columbus, Ohio. This summarizes approximately 325 studies using the Aberrant Behavior Checklist in the developmental disabilities. It also contains approximately 25 translations of the ABC into other languages.
2. Project MED: Medication EDucation for Consumers:
   1. Aman, M.G., Benson, B.A., Campbell, K.M., & Haas, B.A. (1999). Patients' Rights and Responsibilities.
   2. Aman, M.G., Benson, B.A., Campbell, K.M., & Haas, B.A. (2000). Anticonvulsant Medicines. (Medicines for People with Epilepsy).
   3. Aman, M.G., Benson, B.A., Campbell, K.M., & Haas, B.A. (1999). Antipsychotic Medicines.
   4. Aman, M.G., Benson, B.A., Campbell, K.M., & Haas, B.A. (1999). Antidepressant Medicines.
   5. Aman, M.G., Benson, B.A., Campbell, K.M., & Haas, B.A. (1999). Antimanic Medicines (Medicines for People with Mood Problems).
   6. Aman, M.G., Benson, B.A., Campbell, K.M., & Griswold, H. (1999). Antianxiety Medicines.
   7. Aman, M.G., Benson, B.A., Campbell, K.M., & Griswold, H. (1999). Stimulant Medicines.
   8. Aman, M.G., Benson, B.A., Campbell, K.M., Masty, J., & Rohr, A. (2001). Other Behavior Medicines (Blood Pressure Medicines, Naltrexone, and Over the Counter).

These are a series of eight booklets describing psychoactive medicines. The booklets are written at the fourth grade level and are intended largely for a handicapped audience, including patients with mental retardation, autistic disorder, specific reading disorders (dyslexia), severe mental illness, and cognitive decline associated with old age (e.g., early stages of dementia). They are also suitable for children and adolescents and for people whose first language is not English. See Project MED website or e-mail proj.med@osu.edu

Web-Sites of Interest

Project MED
O.S.U. Research Units on Pediatric Psychopharmacology
Nisonger Center
O.S.U. Psychology Department 
Treatment of Severe Childhood Aggression study
CHARTS (Children with Hyperactivity and Autism Research Treatment Study